The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Open accessAbstract
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose. METHODS: In this trial conducted in both northern and southern hemispheres, we evaluated nirsevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation). We randomly assigned the infants in a 2:1 ratio to receive nirsevimab, at a dose of 50 mg in a single intramuscular injection, or placebo at the start of an RSV season. The primary end point was medically attended RSV-associated lower respiratory tract infection through 150 days after administration of the dose. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after administration of the dose. RESULTS: From November 2016 through November 2017, a total of 1453 infants were randomly assigned to receive nirsevimab (969 infants) or placebo (484 infants) at the start of the RSV season. The incidence of medically attended RSV-associated lower respiratory tract infection was 70.1% lower (95% confidence interval [CI], 52.3 to 81.2) with nirsevimab prophylaxis than with placebo (2.6% [25 infants] vs. 9.5% [46 infants]; P<0.001) and the incidence of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower (95% CI, 51.9 to 90.3) with nirsevimab than with placebo (0.8% [8 infants] vs. 4.1% [20 infants]; P<0.001). These differences were consistent throughout the 150-day period after the dose was administered and across geographic locations and RSV subtypes. Adverse events were similar in the two trial groups, with no notable hypersensitivity reactions. CONCLUSIONS: A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants. (Funded by AstraZeneca and Sanofi Pasteur; ClinicalTrials.gov number, NCT02878330.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,371
Self-citationThe Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,246
Self-citationKIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children
Jain, S., Williams, D. J., Arnold, S. R., Ampofo, K., Bramley, A. M., Reed, C., Stockmann, C., Anderson, E. J., Grijalva, C. G., Self, W. H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405870 · Cited by 1,804
Respiratory Syncytial Virus and Parainfluenza Virus
Hall, C. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442507 · Cited by 1,233
O'Brien, K. L., Baggett, H. C., Brooks, W. A., Feikin, D. R., Hammitt, L. L., Higdon, M. M., Howie, S. R. C., Deloria Knoll, M., Kotloff, K. L., Levine, O. S., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30721-4 · Cited by 879
Self-citationFeltes, T. F., Cabalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top, F. H., Connor, E. M., Sondheimer, H. M., & for the Cardiac Synagis Study Group (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00454-2 · Cited by 824
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
Self-citationCOMMITTEE ON INFECTIOUS DISEASES and BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1666 · Cited by 386
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Self-citationA highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 362
Self-citationCarbonell-Estrany, X., Simões, E. A. F., Dagan, R., Hall, C. B., Harris, B., Hultquist, M., Connor, E. M., Losonsky, G. A., & for the Motavizumab Study Group (2010) · Pediatrics · doi:10.1542/peds.2008-1036 · Cited by 236
Domachowske, J. B., Khan, A. A., Esser, M. T., Jensen, K., Takas, T., Villafana, T., Dubovsky, F., & Griffin, M. P. (2018) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001916 · Cited by 228
Self-citationMiller, E. K., Gebretsadik, T., Carroll, K. N., Dupont, W. D., Mohamed, Y. A., Morin, L.-L., Heil, L., Minton, P. A., Woodward, K., Liu, Z., et al. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31829b7e43 · Cited by 204
O'Brien, K. L., Chandran, A., Weatherholtz, R., Jafri, H. S., Griffin, M. P., Bellamy, T., Millar, E. V., Jensen, K. M., Harris, B. S., Reid, R., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00247-9 · Cited by 190
Self-citationGriffin, M. P., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Kankam, M. K., Villafana, T. L., & Dubovsky, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-16 · Cited by 156
Self-citationRobbie, G. J., Zhao, L., Mondick, J. T., Losonsky, G. A., & Roskos, L. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06446-11 · Cited by 150
Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
Simões, E. A. F., DeVincenzo, J. P., Boeckh, M., Bont, L., Crowe, J. E., Griffiths, P. D., Hayden, F. G., Hodinka, R. L., Smyth, R. L., Spencer, K., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu828 · Cited by 130
Self-citationCarroll, K. N., Gebretsadik, T. S., Griffin, M. R., Wu, P., Dupont, W. D., Mitchel, E. F., Enriquez, R., & Hartert, T. V. (2008) · PEDIATRICS · doi:10.1542/peds.2007-2087 · Cited by 129
Self-citationChu, H. Y., Tielsch, J. M., Katz, J., Magaret, A., Khatry, S. K., LeClerq, S. C., Shrestha, L., Kuypers, J. M., Steinhoff, M. C., & Englund, J. A. (2017) · Journal of Clinical Virology · doi:10.1016/j.jcv.2017.08.017 · Cited by 84
Passive and active immunization against respiratory syncytial virus for the young and old
Villafana, T. L., Falloon, J., Griffin, M. P., Zhu, Q., & Esser, M. T. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1333425 · Cited by 59
Self-citationGiersing, B. K., Karron, R. A., Vekemans, J., Kaslow, D. C., & Moorthy, V. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.02.068 · Cited by 56
Hall, C. B., & Walsh, E. E. (1999) · Elsevier eBooks · doi:10.1002/0470842474.ch7 · Cited by 41
Karron, R. A., & Zar, H. J. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30303-x · Cited by 41
Nyiro, J. U., Sande, C., Mutunga, M. N., Kiyuka, P. K., Munywoki, P. K., Scott, J. A. G., & Nokes, D. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166706 · Cited by 31
Cited by
Li, Y., Wang, X., Blau, D. M., Caballero, M. T., Feikin, D. R., Gill, C. J., Madhi, S. A., Omer, S. B., Simões, E. A. F., Campbell, H., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00478-0 · Cited by 1,941
Self-citationPhase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Hammitt, L. L., Dagan, R., Yuan, Y., Baca Cots, M., Bosheva, M., Madhi, S. A., Muller, W. J., Zar, H. J., Brooks, D., Grenham, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110275 · Cited by 1,027
Self-citationRespiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C. L., Eckert, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 420
Gebremedhin, A. T., Hogan, A. B., Blyth, C. C., Glass, K., & Moore, H. C. (2022) · Scientific Reports · doi:10.1038/s41598-021-04080-3 · Cited by 399
Metadata
- Authors
- Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., Villafana, T., & DeVincenzo, J. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-30
- Volume
- 383
- Issue
- 5
- Pages
- 415-425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3046024889
- Cited by
- 762
- References
- 28
- FWCI
- 51.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.